NCT06121830 - Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD) | Biotech Hunter

Enrollment

324

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

March 31, 2025

Conditions

Non-erosive Reflux DiseaseNon-Erosive Gastro-Esophageal Reflux DiseaseNon-Erosive Esophageal Reflux Disease

Interventions

DRUG

DWP14012 20mg

DWP14012 20mg, tablet, orally, once daily for up to 4 weeks

DRUG

DWP14012 40mg

DWP14012 40mg, tablet, orally, once daily for up to 4 weeks

DRUG

Placebo

Placebo, tablet, orally, once daily for up to 4 weeks

Trial Locations (1)

RECRUITING

Wonkwang University Hospital, Iksan